MedTrace Logo

Evaluation of Possible Safety and Efficacy of Fenofibrate in the Prophylaxis of Doxorubicin Induced Cardiotoxicity in Breast Cancer Patients

NCT06155331 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 44

Last updated 2025-08-19

No results posted yet for this study

Summary

This study aims at evaluating the possible safety and efficacy of fenofibrate in attenuating doxorubicin related cardiac toxicity in breast cancer patients.

Conditions

  • Breast Cancer Stage 2 and 3

Interventions

DRUG

Fenofibrate

It is an approved drug for hypercholesterolemia, It lowers lipid levels by activating peroxisome proliferator-activated receptor alpha (PPARα).

OTHER

Placebo

Placebo is made to look exactly like a real drug but is made of an inactive substance.

DRUG

Doxorubicin

Anthracycline derived chemotherapy used in treatment of breast cancer

DRUG

Cyclophosphamide

Alkylating agent used in treatment of breast cancer

Sponsors & Collaborators

  • Tanta University

    lead OTHER

Principal Investigators

  • Hagar Dewidar, Instructor · Tanta University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-12-01
Primary Completion
2025-01-01
Completion
2025-01-01

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06155331 on ClinicalTrials.gov